Left Ventricular Dysfunction After Treatment With Ipilimumab for Metastatic Melanoma.

Roth, Mary E; Muluneh, Benyam; Jensen, Brian C; Madamanchi, Chaitanya; Lee, Carrie B

Roth, Mary E; Muluneh, Benyam; Jensen, Brian C; Madamanchi, Chaitanya; Lee, Carrie B.

Affiliation

Roth ME; 1Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC; 2Division of Cardiology, University of North Carolina Medical Center, Chapel Hill, NC; 3UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC; 4UNC McAllister Heart Institute, Chapel Hill, NC; 5Center for Heart and Vascular Care, University of North Carolina Medical Center, Chapel Hill, NC; 6Department of Medicine, University of North Carolina Medical Center, Chapel Hill, NC; and

Am J Ther ; 23(6): e1925-e1928, 2016.

Article in En | MEDLINE | ID: mdl-26885708

Subject(s)

Antibodies, Monoclonal/adverse effects; Antineoplastic Agents/adverse effects; Atrial Fibrillation/chemically induced; Liver Neoplasms/drug therapy; Melanoma/drug therapy; Skin Neoplasms/pathology; Ventricular Dysfunction, Left/chemically induced; Bundle-Branch Block/complications; Humans; Hypertension/complications; Ipilimumab; Liver Neoplasms/secondary; Male; Melanoma/secondary; Middle Aged; Stroke Volume

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Atrial Fibrillation / Skin Neoplasms / Ventricular Dysfunction, Left / Liver Neoplasms / Melanoma / Antibodies, Monoclonal / Antineoplastic Agents Limits: Humans / Male / Middle aged Language: En Journal: Am J Ther Journal subject: TERAPEUTICA Year: 2016 Type: Article

Search on Google

XML

PubMed Links